{"prompt": "['Trelagliptin-4002', 'Page 30 of 66', 'Version 2.0', 'July 5,10', \"study subject's participation be discontinued, the primary reason for termination shall be recorded on\", 'the CRF by the principal investigator or investigator. In addition, efforts shall be made to perform all', 'tests/observations/evaluations scheduled at the time of discontinuation.', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 31 of 66', 'Version 2.0', 'July 5,2017', '8.0', 'STUDY TREATMENT', 'This section indicates the treatment regimen of this clinical research. See the latest package insert for', 'details and handling of each drug.', '8.1', 'Study drug and Comparative drug', '8.1.1', 'Study drug', 'Generic name: Trelagliptin Succinate', 'Chemical name: 2-(|6-[(3R)-3-Aminopiperidin-1-yl]-3-methyl-2, 4-dioxo-3, 4- dihydropyrimidin', '-', '1(2H)-yl} methyl)-4-fluorobenzonitrile monosuccinate', '<Dose and administration method>', 'Trelagliptin: Trelagliptin 100 mg is orally administered once weekly. Trelagliptin 50 mg is oraly', 'administered once weekly in patients with moderate renal impairment.', '8.1.2 Comparative drug', 'Daily DPP-4 inhibitor: Inhibitors shown in Table 8.a are orally administered at the dosage and', 'administration instructed in the package inserts of each drug.', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 32 of 66', 'Version 2.0', 'July 5, 2017', 'Table 8.a', 'Daily DPP-4 inhibitor', 'Inhibitors', 'Dosage and Administration', 'CCI', 'Sitagliptin:', 'Vildagliptin', 'Alogliptin', 'Take orally in accordance', 'Linagliptin', 'with the instructions in the', 'Teneligliptin', 'package inserts.', 'Anagliptin', 'CCI', 'Saxagliptin', '8.2', 'Overdose of the study drug', 'Overdose is defined as intentional or accidental administration of the study drug or comparative drug', 'at a higher dose than that specified in the package inserts, either by a health professional or by the', 'study subject.', 'To consistently collect important safety information about overdose, the principal investigator or', 'investigator(s) shall record all cases of overdose on the \"Overdose\" page of the CRF, irrespective of', 'the presence or absence of accompanying adverse event. Adverse events associated with overdose', 'shall be recorded on the \"Adverse events\" page of the CRF, in accordance with the procedures', 'described in Section 10.0, \"Adverse Events.\"', 'In addition, serious adverse events associated with overdose shall be recorded in accordance with the', 'procedures described in Section 10.2.2, \"Collection and reporting of serious adverse events.\"', 'In the event of overdose, the principal investigator or investigator shall treat the subject as required', 'based on symptoms.', '8.3', 'Medication other than the study drug and the comparative drug', 'Prohibited concomitant drugs (refer to Section 7.3.1) may not be used. Other treatments shall be', 'conducted under normal medical practice.', 'In principle, concomitant medications cannot be added or withdrawn, and the dosages of', 'concomitant medications cannot be changed during this clinical study period (refer to the section', '7.2). However, the addition of concomitant medications will be allowed as long as the principal', 'investigator or investigator considers its necessity due to reasons such as adverse events. The', 'principal investigator or investigator shall provide directions to study subjects not to take any', 'medications (including over-the-counter drugs) other than the medications instructed to use without', 'prior consultation.', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}